Our data suggest that targeting the NFATc1 signaling in EZH2low TNBC/BLBC patients could represent an attractive opportunity to increase the efficiency of conventional chemotherapeutic treatments and reduce the development of deadly resistant cancer cells phenotypes. This evidence concerns the gene NFATC1 and cancer.